Mink Enterprise Value Over E B I T D A from 2010 to 2024
| INKT Stock | USD 0.70 0.05 6.67% |
Enterprise Value Over EBITDA | First Reported 2010-12-31 | Previous Quarter (1.50) | Current Value (1.58) | Quarterly Volatility 8.84397995 |
Check Mink Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Mink Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 584.4 K, Depreciation And Amortization of 118.7 K or Interest Expense of 216.6 K, as well as many indicators such as Price To Sales Ratio of 0.0355, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. Mink financial statements analysis is a perfect complement when working with Mink Therapeutics Valuation or Volatility modules.
Mink | Enterprise Value Over E B I T D A |
Latest Mink Therapeutics' Enterprise Value Over E B I T D A Growth Pattern
Below is the plot of the Enterprise Value Over E B I T D A of Mink Therapeutics over the last few years. It is Mink Therapeutics' Enterprise Value Over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Mink Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Enterprise Value Over E B I T D A | 10 Years Trend |
|
Enterprise Value Over E B I T D A |
| Timeline |
Mink Enterprise Value Over E B I T D A Regression Statistics
| Arithmetic Mean | (15.46) | |
| Coefficient Of Variation | (57.20) | |
| Mean Deviation | 7.01 | |
| Median | (19.07) | |
| Standard Deviation | 8.84 | |
| Sample Variance | 78.22 | |
| Range | 30.3832 | |
| R-Value | 0.60 | |
| Mean Square Error | 53.56 | |
| R-Squared | 0.36 | |
| Significance | 0.02 | |
| Slope | 1.19 | |
| Total Sum of Squares | 1,095 |
Mink Enterprise Value Over E B I T D A History
About Mink Therapeutics Financial Statements
Mink Therapeutics shareholders use historical fundamental indicators, such as Enterprise Value Over E B I T D A, to determine how well the company is positioned to perform in the future. Although Mink Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Mink Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Mink Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Enterprise Value Over EBITDA | (1.50) | (1.58) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Mink Stock Analysis
When running Mink Therapeutics' price analysis, check to measure Mink Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mink Therapeutics is operating at the current time. Most of Mink Therapeutics' value examination focuses on studying past and present price action to predict the probability of Mink Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mink Therapeutics' price. Additionally, you may evaluate how the addition of Mink Therapeutics to your portfolios can decrease your overall portfolio volatility.